X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SANOFI INDIA LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

SANOFI INDIA LIMITED  (HOCM)


Here is the latest financial fact sheet of Aventis Pharma. For more details, see the Aventis Pharma quarterly results and Aventis Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
sanofi india - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 4,481.5       No. of shares m 23.03
    Mkt Cap Rs m 103,209       % ch % -1.3
    Vol '000 0.4       % ch week % -3.9
    P/E X 34.5       % ch 1-mth % -2.0
    P/CF X 23.8       % ch 12-mth % 6.6
    EPS (TTM) Rs 129.8       52 week H/L Rs 4,930.0/4,005.0
(As on Apr 21, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Dec-11
12
Dec-12
12
Dec-13
12
Dec-14
12
Dec-15
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs2,4242,3992,8623,8004,521 
Low Rs1,7702,1962,4502,5003,445 
Sales per share (Unadj.) Rs565.1683.0785.4858.7952.3 
Earnings per share (Unadj.) Rs83.076.7115.1114.5139.6 
Diluted earnings per shareRs83.076.7115.1114.5139.6 
Cash flow per share (Unadj.) Rs96.5115.7155.2156.4188.7 
Dividends per share (Unadj.) Rs33.0033.0045.0045.0065.00 
Adj. dividends per shareRs33.0033.0045.0045.0065.00 
Dividend yield (eoy) %1.61.41.71.41.6 
Book value per share (Unadj.) Rs484.9522.8584.8645.2706.5 
Adj. book value per shareRs484.9522.8584.8645.2706.5 
Shares outstanding (eoy) m23.0323.0323.0323.0323.03 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x3.73.43.43.74.2 
Avg P/E ratio x25.330.023.127.528.5 
P/CF ratio (eoy) x21.719.917.120.121.1 
Price / Book Value ratio x4.34.44.54.95.6 
Dividend payout %39.843.039.139.346.6 
Avg Mkt Cap Rs m48,29452,91161,16872,54591,724 
No. of employees `0002.93.23.33.43.7 
Total wages/salary Rs m1,7642,1382,4212,8823,333 
Avg. sales/employee Rs Th4,421.84,971.75,496.45,735.25,987.0 
Avg. wages/employee Rs Th599.5675.7735.7836.0909.9 
Avg. net profit/employee Rs Th649.6558.3805.8764.5877.7 
  INCOME DATA
Net Sales Rs m13,01315,73018,08919,77521,930 
Other income Rs m679412579643514 
Total revenues Rs m13,69216,14218,66720,41822,444 
Gross profit Rs m2,4773,1183,9793,3894,591 
Depreciation Rs m3128999239661,130 
Interest Rs m414454 
Profit before tax Rs m2,8402,6173,6313,0613,970 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00254666839 
Tax Rs m9288511,2331,0901,594 
Profit after tax Rs m1,9121,7672,6522,6363,215 
Gross profit margin %19.019.822.017.120.9 
Effective tax rate %32.732.534.035.640.1 
Net profit margin %14.711.214.713.314.7 
  BALANCE SHEET DATA
Current assets Rs m6,6678,2879,47112,62812,437 
Current liabilities Rs m3,5693,8664,6896,5586,170 
Net working cap to sales %23.828.126.430.728.6 
Current ratio x1.92.12.01.92.0 
Inventory Days Days7163698880 
Debtors Days Days2923242124 
Net fixed assets Rs m7,5987,4288,3488,5828,771 
Share capital Rs m230230230230230 
"Free" reserves Rs m10,78211,66513,09914,55916,004 
Net worth Rs m11,16612,04113,46714,85816,272 
Long term debt Rs m00000 
Total assets Rs m15,02516,31318,78322,27624,046 
Interest coverage x677.1187.9865.5638.6993.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.91.01.00.90.9 
Return on assets %12.810.914.111.913.4 
Return on equity %17.114.719.717.719.8 
Return on capital %25.521.928.925.129.6 
Exports to sales %16.915.623.024.224.2 
Imports to sales %29.527.530.236.926.1 
Exports (fob) Rs m2,1952,4474,1524,7885,312 
Imports (cif) Rs m3,8334,3265,4557,2985,720 
Fx inflow Rs m3,0503,2034,8655,4956,680 
Fx outflow Rs m4,6864,8656,0948,0456,587 
Net fx Rs m-1,637-1,662-1,229-2,55093 
  CASH FLOW
From Operations Rs m 2,050 2,898 2,726 2,650 2,132 
From Investments Rs m -4,789 -54 -3,354 613 359 
From Financial Activity Rs m -1,472 -897 -1,050 -1,217 -1,470 
Net Cashflow Rs m -4,211 1,946 -1,678 2,046 1,021 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for sanofi india limited

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 60.4%
Indian inst/Mut Fund : 14.4%
FIIs : 14.6%
ADR/GDR : 0.0%
Free float : 10.5%
Shareholders : 15,184
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Aventis House, 54/A, Mathuradas Vasanji Road, Andheri (E), Mumbai-93
    E-MAIL: k.subramani@sanofi.com     WEB: www.sanofiindialtd.com
    TELEPHONE: (022) 2827 8000     FAX: (022) 2837 0939
    SECTOR: PHARMACEUTICALS     GROUP: M N C
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
    AUDITOR: S. R. Batliboi & Co.
CHM: Vijay Mallya COMP SEC: K. Subramani YEAR OF INC: 1956 BSE CODE: 500674 FV (Rs): 10 DIV YIELD (%): 1.5

More pharmaceuticals Company Fact Sheets:   CADILA HEALTHCAREASTRAZENECA PHARMAUNICHEM LABELDER PHARMAAMAR REMEDIES


Today's Market

Corporate Debt, a Achilles' Heel for Indian Banks(Pre-Open)

Credit indebtness of India Inc continues to bog down the country's banking system. Measures taken by the government and RBI have also not met with much progress.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

Why Suddenly There is No Cash in ATMs(Vivek Kaul's Diary)

Apr 11, 2017

There have been a spate of media reports around ATMs not dispensing cash. What is really happening here?

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

Is PPF As An Investment Avenue Dead?(Outside View)

Apr 11, 2017

It's true, the interest on PPF has been lowered to 7.9%. PersonalFN evaluates if it's still a promising investment avenue.

More

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SANOFI INDIA

SANOFI INDIA - ACTAVIS COMPARISON

Compare Company With Charts

COMPARE SANOFI INDIA WITH

MARKET STATS